Xenon (XENE) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Xenon Pharmaceuticals is set to present new long-term data on azetukalner, a promising treatment for focal onset seizures, at the American Epilepsy Society Annual Meeting. This includes insights into the mental health and comorbidity burdens associated with the condition. Additionally, Xenon will share developments from its Nav1.1 program, highlighting its innovative research approach.
For further insights into XENE stock, check out TipRanks’ Stock Analysis page.
